drugset / Trial / NCT04803851
Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1 antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer patients, in order to find a better therapy strategy for pancreatic cancer patients.
Timeline
- Start
- 2021-05-12
- Primary completion
- 2024-02-28
- Completion
- 2024-06-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | — | — |
| Subject | Penpulimab | Monoclonal antibody | — | — |